|
Adverse event
|
Entire cohort (n, %)
|
CC-CCD group (n, %)
|
P valuea
|
|---|
|
< 160 mg/m2
|
≥ 160 mg/m2
|
|---|
|
Acute toxicity (n = 132)
| |
n = 52
|
n = 80
| |
|
Mucositis
|
57 (43.2)
|
21 (40.4)
|
36 (45.0)
|
0.719
|
|
Nausea
|
23 (17.4)
|
10 (19.2)
|
13 (16.3)
|
0.648
|
|
Leucopenia
|
35 (26.5)
|
14 (26.9)
|
21 (26.3)
|
0.996
|
|
Neutropenia
|
18 (13.6)
|
9 (17.3)
|
9 (11.3)
|
0.437
|
|
Anemia
|
5 (3.8)
|
1 (1.9)
|
4 (5.0)
|
0.648
|
|
Thrombocytopenia
|
2 (1.5)
|
1 (1.9)
|
1 (1.3)
|
0.997
|
|
Late toxicity (n = 115)
| |
n = 43
|
n = 72
| |
|
Xerostomia
|
11 (9.6)
|
5 (11.6)
|
6 (8.3)
|
0.723
|
|
Ototoxicity
|
9 (7.8)
|
4 (9.3)
|
5 (6.9)
|
0.726
|
|
Neck fibrosis
|
6 (5.2)
|
2 (4.7)
|
4 (5.6)
|
0.992
|
|
Hypothyroidism
|
3 (2.6)
|
2 (4.7)
|
1 (1.4)
|
0.555
|
- CC-CCD cumulative cisplatin dose during concurrent chemoradiotherapy
- aP values were calculated using the chi-square test or Fisher exact test if indicated
